Oncotelic Therapeutics, Inc. Finite-Lived Intangible Asset, Expected Amortization, Year One
Oncotelic Therapeutics, Inc. (OTLC) had Finite-Lived Intangible Asset, Expected Amortization, Year One of $38.52 thousand as of 2021-12-31, per its 10-Q filed 2022-05-23.
Discontinued › Notes › Intangible Asset, Finite-Lived, and Capitalized Cost, Software to be Sold, Leased, or Marketed, Estimated Amortization Expense › Intangible Asset, Finite-Lived, after Accumulated Amortization, Estimated Amortization Expense, Fiscal Year Maturity
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths · last filed 2022-05-23
- 2021-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year One $38.52K; Finite-Lived Intangible Asset, Expected Amortization, Year One as first filed $51.37K.
- 2021-09-30: Finite-Lived Intangible Asset, Expected Amortization, Year One $51.37K.
- 2021-06-30: Finite-Lived Intangible Asset, Expected Amortization, Year One $51.37K.
- 2021-03-31: Finite-Lived Intangible Asset, Expected Amortization, Year One $51.37K.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Year One | Finite-Lived Intangible Asset, Expected Amortization, Year One as first filed |
|---|---|---|
| 2021-12-31 | $38.52K 10-Q · filed 2022-05-23 | $51.37K 10-K · filed 2022-04-15 |
| 2021-09-30 | $51.37K 10-Q · filed 2021-11-22 | |
| 2021-06-30 | $51.37K 10-Q · filed 2021-08-20 | |
| 2021-03-31 | $51.37K 10-Q · filed 2021-05-24 | |
| 2020-12-31 | $51.37K 10-K · filed 2021-04-15 | |
| 2020-09-30 | $51.37K 10-Q · filed 2020-11-16 | |
| 2019-06-30 | $51.37K 10-Q · filed 2019-08-19 |